I believe Covid sped up the maturity of Cytodyn. I have read many people who have owned the stock for years how frustrating sometimes they have been with the ups and downs of the Company I came on board early this year and saw some of the immaturity in play but once the phase 2/3 trial kicked in last April and the EIND anecdotal results looked good it sped up some things Cytodyn needed to do in order to have a drug ready for market .in the last few months , the company has added very important resources to manage first hand, the BLA processes which was a glaring issue, as well as bringing in a CSO and adding an advisory board of doctors from different practices known in the industry. The decisions now are very good and the latest which is putting someone out in the field to accelerate the visibility of Leronlimab and get more patients in the trials faster is going to work. Turning up manufacturing with Samsung and extending out to other nations to prepare to be a global presence in the Pharma business is also happening.
So once the drug is approved for Covid, The brand of Cytodyn in the industry will be established. And as Dr. Kelly mentioned, the threshold for drug approval in the cancer area is much easier because any drug which can treat patients who are dying from cancer will get approval..The bar is much lower for drugs treating late stage patients.